New trial
Phase II GT103 mAb targeting complement factor H with pembrolizumab for STK11 NSCLC
- Trial ID
- NCT07017829 on ClinicalTrials.gov
- Cancer type
- NSCLC
- Stage of research
- Exploratory
- Published in
- New in Oncology - July 3, 2025
This study tests GT103 with pembrolizumab as a combination immunotherapy for advanced STK11 mutant non‐small cell lung cancer. Sponsored by Roswell Park Cancer Institute, the trial evaluates GT103’s novel complement factor H targeting in a Phase II setting to potentially improve outcomes.
More in non-small cell lung cancer
-
Trial result · Oct 22, 2026 · NCT04905316
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC -
Trial result · Oct 15, 2026 · NCT04495153
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group -
New trial · Oct 15, 2026 · NCT07852247
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC -
New trial · Oct 15, 2026 · NCT07617337
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC -
Trial result · Oct 8, 2026 · NCT03052608
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC